These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 34108096)

  • 1. MAFLD vs NAFLD: Where are we?
    Mantovani A
    Dig Liver Dis; 2021 Oct; 53(10):1368-1372. PubMed ID: 34108096
    [No Abstract]   [Full Text] [Related]  

  • 2. NAFLD, MAFLD and DAFLD.
    Mantovani A; Dalbeni A
    Dig Liver Dis; 2020 Dec; 52(12):1519-1520. PubMed ID: 33012657
    [No Abstract]   [Full Text] [Related]  

  • 3. Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy?
    Kjær MB; George J; Kazankov K; Grønbæk H
    Expert Rev Gastroenterol Hepatol; 2021 Jan; 15(1):51-64. PubMed ID: 32878486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pathologic relevance of metabolic criteria in patients with biopsy-proven nonalcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease: A multicenter cross-sectional study in China.
    Yang RX; Zou ZS; Zhong BH; Deng H; He FP; Shi JP; Zhao CY; Mi YQ; Zhou YJ; Di FS; Zheng RD; Du Q; Shang J; Popovic B; Chen J; Fan JG
    Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):426-432. PubMed ID: 34246549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From non-alcoholic fatty liver disease (NAFLD) to metabolic-associated fatty liver disease (MAFLD): A journey over 40 years.
    Kuchay MS; Misra A
    Diabetes Metab Syndr; 2020; 14(4):695-696. PubMed ID: 32442920
    [No Abstract]   [Full Text] [Related]  

  • 6. Simultaneous Metabolic and Alcohol-associated Fatty Liver Disease (SMAFLD) and Simultaneous Metabolic and Alcohol-associated Steatohepatitis (SMASH).
    Senussi NH; McCarthy DM
    Ann Hepatol; 2021; 24():100526. PubMed ID: 34509272
    [No Abstract]   [Full Text] [Related]  

  • 7. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognosis of MAFLD vs. NAFLD and implications for a nomenclature change.
    Wong VW; Lazarus JV
    J Hepatol; 2021 Dec; 75(6):1267-1270. PubMed ID: 34464658
    [No Abstract]   [Full Text] [Related]  

  • 9. Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options.
    Milic S; Mikolasevic I; Krznaric-Zrnic I; Stanic M; Poropat G; Stimac D; Vlahovic-Palcevski V; Orlic L
    Drug Des Devel Ther; 2015; 9():4835-45. PubMed ID: 26316717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic Fatty Liver Disease.
    Sweet PH; Khoo T; Nguyen S
    Prim Care; 2017 Dec; 44(4):599-607. PubMed ID: 29132522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of the ELF Test for Detecting Steatohepatitis in Morbid Obese Patients with Suspicion of Nonalcoholic Fatty Liver Disease.
    López IC; Aroca FG; Bernal MDF; Mompeán JAL; Bernal ÁB; Martínez AMH; Barba EM; Velasco JAN; Paricio PP
    Obes Surg; 2017 Sep; 27(9):2347-2353. PubMed ID: 28229316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
    Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
    Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effects of Metabolic Surgery on Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    Clanton J; Subichin M
    Surg Clin North Am; 2016 Aug; 96(4):703-15. PubMed ID: 27473796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-alcoholic fatty liver disease and thyroid dysfunction: a systematic review.
    Eshraghian A; Hamidian Jahromi A
    World J Gastroenterol; 2014 Jul; 20(25):8102-9. PubMed ID: 25009382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leptin in nonalcoholic fatty liver disease: a narrative review.
    Polyzos SA; Kountouras J; Mantzoros CS
    Metabolism; 2015 Jan; 64(1):60-78. PubMed ID: 25456097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].
    Kim SK; Kim KI; Kim SR
    Yakugaku Zasshi; 2019; 139(9):1147-1153. PubMed ID: 31474630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
    Manne V; Handa P; Kowdley KV
    Clin Liver Dis; 2018 Feb; 22(1):23-37. PubMed ID: 29128059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic Fatty Liver Disease: Pathophysiology and Management.
    Carr RM; Oranu A; Khungar V
    Gastroenterol Clin North Am; 2016 Dec; 45(4):639-652. PubMed ID: 27837778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update.
    Barchetta I; Cimini FA; Cavallo MG
    Nutrients; 2020 Oct; 12(11):. PubMed ID: 33126575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.